drugset / Trial / NCT06463548
Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |